A Six-Period Crossover, Dose-Ranging Study to Evaluate the Efficacy and Safety of Four Doses of FS Spiromax (Fluticasone Propionate/Salmeterol Xinafoate Inhalation Powder) Administered as Single Doses Compared With Single Doses of Fluticasone Propionate Spiromax and Open Label Advair Diskus in Adult and Adolescent Subjects With Persistent Asthma
Phase of Trial: Phase II
Latest Information Update: 14 Jun 2017
At a glance
- Drugs Salmeterol/fluticasone propionate (Primary) ; Fluticasone propionate
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Teva Pharmaceutical Industries
- 28 Jun 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 30 Jan 2013 New trial record
- 01 Jan 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.